Home
HelpOrder Code CRDPP Creatine Disorders Panel, Plasma
Ordering Guidance
For additional diagnostic testing, consider ordering CRDPU / Creatine Disorders Panel, Random, Urine.
Additional Testing Requirements
To diagnose all creatine deficiency syndromes, order CRDPU / Creatine Disorders Panel, Random, Urine in addition to this test.
Necessary Information
Patient's age and sex are required.
Specimen Required
Collection Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Green top (sodium heparin), yellow top (ACD)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot plasma into plastic vial. Send plasma frozen.
Useful For
Evaluating patients with a clinical suspicion of arginine:glycine amidinotransferase deficiency, guanidinoacetate methyltransferase deficiency, and creatine transporter deficiency using plasma specimens
Genetics Test Information
Depletion of cerebral creatine occurs in all 3 types of creatine deficiency syndromes (CDS): arginine:glycine amidinotransferase deficiency, guanidinoacetate methyltransferase deficiency, and creatine transporter deficiency.
Measurement of guanidinoacetate, creatine, and creatinine, along with associated analyte ratios in plasma and urine, aids in distinguishing the types of creatine deficiency syndromes.
Treatment with oral creatine supplementation is effective in some types of CDS.
Creatine supplementation may impact reliability of test results.
Testing Algorithm
For more information see:
-Newborn Screen Follow-up for Guanidinoacetate Methyltransferase Deficiency
-Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
If the patient has abnormal newborn screening results for guanidinoacetate methyltransferase deficiency, refer to the appropriate ACMG Newborn Screening ACT Sheet.(1)
Special Instructions
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Creatine Disorders Panel, PSpecimen Type
PlasmaSpecimen Minimum Volume
0.1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma | Frozen (preferred) | 14 days | |
| Refrigerated | 7 days | ||
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Reference Values
|
Creatine Disorders Panel Reference Values |
||||||||||||
|
|
≤11 Months |
12-23 Months |
24-35 Months |
|||||||||
|
Female |
Male |
Female |
Male |
Female |
Male |
|||||||
|
Creatine |
38.6-96.8 |
39.0-97.0 |
38.2-96.5 |
38.6-96.5 |
37.7-96.0 |
38.2-96.0 |
||||||
|
Creatinine |
27.6-35.9 |
27.6-35.2 |
27.6-36.5 |
27.6-35.5 |
27.6-37.1 |
27.6-36.0 |
||||||
|
Guanidinoacetate |
0.7-2.0 |
0.7-2.1 |
0.7-2.0 |
0.7-2.1 |
0.7-2.0 |
0.7-2.1 |
||||||
|
Creatine/ |
≤3.07 |
≤3.60 |
≤3.02 |
≤3.54 |
≤2.96 |
≤3.48 |
||||||
|
Guanidinoacetate/ |
≤0.040 |
≤0.040 |
≤0.042 |
≤0.040 |
≤0.043 |
≤0.042 |
||||||
|
Guanidinoacetate/ |
≤0.051 |
≤0.081 |
≤0.051 |
≤0.080 |
≤0.051 |
≤0.079 |
||||||
|
|
||||||||||||
|
|
3 Years |
4 Years |
5 Years |
|||||||||
|
Female |
Male |
Female |
Male |
Female |
Male |
|||||||
|
Creatine |
37.1-95.5 |
37.7-95.3 |
36.0-94.4 |
36.8-94.1 |
34.6-93.2 |
35.6-92.7 |
||||||
|
Creatinine |
27.6-37.9 |
27.7-36.9 |
27.6-39.3 |
27.7-38.2 |
27.6-40.9 |
27.8-39.9 |
||||||
|
Guanidinoacetate |
0.7-2.1 |
0.7-2.2 |
0.7-2.1 |
0.7-2.2 |
0.7-2.1 |
0.7-2.2 |
||||||
|
Creatine/ |
≤2.89 |
≤3.40 |
≤2.77 |
≤3.26 |
≤2.64 |
≤3.09 |
||||||
|
Guanidinoacetate/ |
≤0.045 |
≤0.043 |
≤0.049 |
≤0.045 |
≤0.053 |
≤0.049 |
||||||
|
Guanidinoacetate/ |
≤0.050 |
≤0.077 |
≤0.050 |
≤0.075 |
≤0.049 |
≤0.072 |
||||||
|
|
6 Years |
7 Years |
8 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
33.0-91.7 |
34.3-91.0 |
31.2-90.0 |
32.7-89.2 |
29.2-88.1 |
31.0-87.3 |
|
Creatinine |
27.6-42.8 |
28.0-41.9 |
27.7-44.9 |
28.3-44.3 |
27.8-47.0 |
28.8-47.1 |
|
Guanidinoacetate |
0.7-2.1 |
0.7-2.3 |
0.7-2.1 |
0.8-2.3 |
0.8-2.1 |
0.8-2.4 |
|
Creatine/ |
≤2.49 |
≤2.91 |
≤2.33 |
≤2.70 |
≤2.17 |
≤2.49 |
|
Guanidinoacetate/ |
≤0.058 |
≤0.053 |
≤0.063 |
≤0.058 |
≤0.069 |
≤0.064 |
|
Guanidinoacetate/ |
≤0.049 |
≤0.069 |
≤0.048 |
≤0.066 |
≤0.047 |
≤0.063 |
|
|
9 Years |
10 Years |
11 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
27.2-85.9 |
29.3-85.2 |
25.2-83.7 |
27.4-83.1 |
23.4-81.3 |
25.7-80.9 |
|
Creatinine |
28.0-49.3 |
29.5-50.1 |
28.2-51.5 |
30.6-53.6 |
28.4-53.6 |
32.0-57.2 |
|
Guanidinoacetate |
0.8-2.2 |
0.8-2.5 |
0.9-2.2 |
0.9-2.6 |
0.9-2.2 |
1.0-2.6 |
|
Creatine/ |
≤2.02 |
≤2.28 |
≤1.86 |
≤2.07 |
≤1.72 |
≤1.87 |
|
Guanidinoacetate/ |
≤0.075 |
≤0.070 |
≤0.081 |
≤0.078 |
≤0.087 |
≤0.085 |
|
Guanidinoacetate/ |
≤0.047 |
≤0.060 |
≤0.046 |
≤0.057 |
≤0.045 |
≤0.055 |
|
|
12 Years |
13 Years |
14 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
21.7-78.7 |
23.9-78.6 |
20.3-76.2 |
22.3-76.2 |
19.0-73.6 |
20.8-73.8 |
|
Creatinine |
28.7-55.7 |
33.8-61.0 |
29.1-57.7 |
35.9-64.8 |
29.5-59.5 |
38.1-68.5 |
|
Guanidinoacetate |
0.9-2.2 |
1.0-2.7 |
1.0-2.3 |
1.1-2.8 |
1.0-2.3 |
1.1-2.9 |
|
Creatine/ |
≤1.58 |
≤1.68 |
≤1.45 |
≤1.50 |
≤1.33 |
≤1.34 |
|
Guanidinoacetate/ |
≤0.092 |
≤0.093 |
≤0.097 |
≤0.101 |
≤0.101 |
≤0.109 |
|
Guanidinoacetate/ |
≤0.044 |
≤0.053 |
≤0.043 |
≤0.051 |
≤0.042 |
≤0.050 |
|
|
15 Years |
16 Years |
17 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
18.1-71.1 |
19.5-71.2 |
17.4-68.7 |
18.4-68.6 |
16.9-66.5 |
17.4-65.9 |
|
Creatinine |
29.9-61.3 |
40.4-71.9 |
30.4-62.9 |
42.4-75.0 |
30.9-64.4 |
44.2-77.6 |
|
Guanidinoacetate |
1.0-2.3 |
1.2-2.9 |
1.1-2.3 |
1.3-3.0 |
1.1-2.3 |
1.3-3.1 |
|
Creatine/ |
≤1.22 |
≤1.20 |
≤1.12 |
≤1.07 |
≤1.04 |
≤0.97 |
|
Guanidinoacetate/ |
≤0.104 |
≤0.117 |
≤0.107 |
≤0.125 |
≤0.109 |
≤0.132 |
|
Guanidinoacetate/ |
≤0.041 |
≤0.049 |
≤0.040 |
≤0.048 |
≤0.040 |
≤0.048 |
|
|
18 Years |
19 Years |
20 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.7-64.4 |
16.6-63.3 |
16.6-62.7 |
15.8-60.7 |
16.5-61.1 |
15.2-58.3 |
|
Creatinine |
31.3-65.8 |
45.6-80.0 |
31.8-67.0 |
46.7-82.0 |
32.2-68.2 |
47.4-83.9 |
|
Guanidinoacetate |
1.1-2.4 |
1.4-3.1 |
1.1-2.4 |
1.4-3.2 |
1.1-2.4 |
1.5-3.2 |
|
Creatine/ |
≤0.98 |
≤0.87 |
≤0.93 |
≤0.80 |
≤0.89 |
≤0.73 |
|
Guanidinoacetate/ |
≤0.111 |
≤0.139 |
≤0.112 |
≤0.145 |
≤0.113 |
≤0.150 |
|
Guanidinoacetate/ |
≤0.039 |
≤0.047 |
≤0.038 |
≤0.047 |
≤0.038 |
≤0.046 |
|
|
21 Years |
22 Years |
23 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.6-59.8 |
14.7-56.0 |
16.6-58.8 |
14.2-54.0 |
16.7-57.9 |
13.7-52.2 |
|
Creatinine |
32.5-69.2 |
47.9-85.6 |
 32.8-70.2 |
48.2-87.2 |
 33.1-71.1 |
48.4-88.8 |
|
Guanidinoacetate |
1.1-2.4 |
1.5-3.2 |
1.1-2.5 |
1.5-3.3 |
1.1-2.5 |
1.6-3.3 |
|
Creatine/ |
≤0.87 |
≤0.68 |
≤0.85 |
≤0.64 |
≤0.84 |
≤0.61 |
|
Guanidinoacetate/ |
≤0.114 |
≤0.156 |
≤0.115 |
≤0.161 |
≤0.116 |
≤0.165 |
|
Guanidinoacetate/ |
≤0.037 |
≤0.045 |
≤0.037 |
≤0.045 |
≤0.037 |
≤0.044 |
|
|
24 Years |
25 Years |
26 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.7-57.2 |
13.3-50.6 |
16.7-56.5 |
12.9-49.3 |
16.7-56.0 |
12.5-48.1 |
|
Creatinine |
33.3-71.9 |
48.6-90.2 |
33.6-72.8 |
48.7-91.5 |
33.7-73.6 |
48.9-92.7 |
|
Guanidinoacetate |
1.1-2.5 |
1.6-3.3 |
1.1-2.5 |
1.6-3.3 |
1.1-2.6 |
1.6-3.4 |
|
Creatine/ |
≤0.84 |
≤0.58 |
≤0.84 |
≤0.56 |
≤0.84 |
≤0.54 |
|
Guanidinoacetate/ |
≤0.116 |
≤0.170 |
≤0.117 |
≤0.174 |
≤0.118 |
≤0.179 |
|
Guanidinoacetate/ |
≤0.036 |
≤0.043 |
≤0.036 |
≤0.043 |
≤0.036 |
≤0.042 |
|
|
27 Years |
28 Years |
29 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.7-55.5 |
12.1-47.1 |
16.6-55.1 |
11.8-46.3 |
16.5-54.7 |
11.5-45.4 |
|
Creatinine |
33.9-74.4 |
49.0-93.7 |
34.1-75.2 |
49.1-94.5 |
34.2-76.0 |
49.2-95.3 |
|
Guanidinoacetate |
1.1-2.6 |
1.6-3.4 |
1.1-2.6 |
1.6-3.4 |
1.1-2.6 |
1.6-3.4 |
|
Creatine/ |
≤0.84 |
≤0.52 |
≤0.84 |
≤0.51 |
≤0.84 |
≤0.49 |
|
Guanidinoacetate/ |
≤0.118 |
≤0.182 |
≤0.119 |
≤0.186 |
≤0.119 |
≤0.188 |
|
Guanidinoacetate/ |
≤0.036 |
≤0.042 |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.041 |
|
|
30 Years |
31 Years |
32 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.4-54.2 |
11.3-44.7 |
16.4-53.8 |
11.1-43.9 |
16.3-53.4 |
11.0-43.2 |
|
Creatinine |
34.4-76.8 |
49.3-96.0 |
34.6-77.5 |
49.3-96.7 |
34.7-78.2 |
49.4-97.4 |
|
Guanidinoacetate |
1.2-2.7 |
1.6-3.5 |
1.2-2.7 |
1.6-3.5 |
1.2-2.7 |
1.6-3.5 |
|
Creatine/ |
≤0.84 |
≤0.48 |
≤0.83 |
≤0.47 |
≤0.83 |
≤0.46 |
|
Guanidinoacetate/ |
≤0.120 |
≤0.190 |
≤0.120 |
≤0.192 |
≤0.119 |
≤0.192 |
|
Guanidinoacetate/ |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.042 |
≤0.037 |
≤0.042 |
|
|
33 Years |
34 Years |
35 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.3-53.0 |
10.9-42.5 |
16.4-52.7 |
10.8-41.7 |
16.4-52.3 |
10.7-41.0 |
|
Creatinine |
34.9-78.8 |
49.4-98.0 |
35.1-79.4 |
49.5-98.6 |
35.3-79.9 |
49.5-99.2 |
|
Guanidinoacetate |
1.2-2.8 |
1.6-3.5 |
1.2-2.8 |
1.6-3.5 |
1.2-2.8 |
1.6-3.4 |
|
Creatine/ |
≤0.82 |
≤0.45 |
≤0.82 |
≤0.45 |
≤0.82 |
≤0.44 |
|
Guanidinoacetate/ |
≤0.119 |
≤0.192 |
≤0.118 |
≤0.191 |
≤0.118 |
≤0.189 |
|
Guanidinoacetate/ |
≤0.037 |
≤0.042 |
≤0.037 |
≤0.042 |
≤0.037 |
≤0.042 |
|
|
36 Years |
37 Years |
38 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
16.5-52.0 |
10.7-40.2 |
16.7-51.6 |
10.6-39.5 |
16.9-51.3 |
10.6-38.9 |
|
Creatinine |
35.4-80.3 |
49.5-99.8 |
35.6-80.7 |
49.5-100.3 |
35.8-81.0 |
49.6-100.8 |
|
Guanidinoacetate |
1.2-2.8 |
1.6-3.4 |
1.2-2.8 |
1.6-3.4 |
1.2-2.9 |
1.6-3.4 |
|
Creatine/ |
≤0.82 |
≤0.44 |
≤0.82 |
≤0.44 |
≤0.83 |
≤0.44 |
|
Guanidinoacetate/ |
≤0.117 |
≤0.187 |
≤0.115 |
≤0.184 |
≤0.114 |
≤0.182 |
|
Guanidinoacetate/ |
≤0.037 |
≤0.042 |
≤0.037 |
≤0.042 |
≤0.036 |
≤0.042 |
|
|
39 Years |
40 Years |
41 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
17.1-51.1 |
10.6-38.2 |
17.3-50.9 |
10.7-37.7 |
17.5-50.8 |
10.7-37.2 |
|
Creatinine |
35.9-81.4 |
49.6-101.3 |
36.0-81.6 |
49.6-101.7 |
36.1-81.9 |
49.7-102.1 |
|
Guanidinoacetate |
1.2-2.9 |
1.6-3.4 |
1.2-2.9 |
1.6-3.4 |
1.2-2.9 |
1.6-3.4 |
|
Creatine/ |
≤0.83 |
≤0.44 |
≤0.83 |
≤0.44 |
≤0.84 |
≤0.44 |
|
Guanidinoacetate/ |
≤0.113 |
≤0.179 |
≤0.111 |
≤0.176 |
≤0.110 |
≤0.174 |
|
Guanidinoacetate/ |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.041 |
≤0.036 |
≤0.040 |
|
|
42 Years |
43 Years |
44 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
17.7-50.8 |
10.8-36.7 |
17.8-50.8 |
10.9-36.3 |
17.8-50.9 |
11.0-36.0 |
|
Creatinine |
36.2-82.1 |
49.7-102.5 |
36.3-82.4 |
49.8-102.8 |
36.4-82.6 |
49.8-103.1 |
|
Guanidinoacetate |
1.2-3.0 |
1.6-3.3 |
1.2-3.0 |
1.6-3.3 |
1.2-3.0 |
1.6-3.3 |
|
Creatine/ |
≤0.84 |
≤0.44 |
≤0.84 |
≤0.43 |
≤0.84 |
≤0.43 |
|
Guanidinoacetate/ |
≤0.109 |
≤0.172 |
≤0.108 |
≤0.171 |
≤0.107 |
≤0.170 |
|
Guanidinoacetate/ |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.038 |
|
|
45 Years |
46 Years |
47 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
17.7-51.0 |
11.1-35.6 |
17.6-51.2 |
11.2-35.3 |
17.4-51.4 |
11.3-35.1 |
|
Creatinine |
36.4-82.8 |
49.9-103.4 |
36.5-83.0 |
49.9-103.6 |
36.5-83.2 |
49.9-103.9 |
|
Guanidinoacetate |
1.2-3.0 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
|
Creatine/ |
≤0.84 |
≤0.42 |
≤0.83 |
≤0.41 |
≤0.83 |
≤0.40 |
|
Guanidinoacetate/ |
≤0.106 |
≤0.169 |
≤0.106 |
≤0.168 |
≤0.106 |
≤0.167 |
|
Guanidinoacetate/ |
≤0.037 |
≤0.038 |
≤0.037 |
≤0.037 |
≤0.037 |
≤0.037 |
|
|
48 Years |
49 Years |
50 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
17.2-51.7 |
11.5-34.8 |
17.1-51.9 |
11.6-34.6 |
17.0-52.1 |
11.7-34.4 |
|
Creatinine |
36.6-83.4 |
49.9-104.1 |
36.6-83.5 |
49.9-104.2 |
36.7-83.7 |
49.9-104.4 |
|
Guanidinoacetate |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.3 |
|
Creatine/ |
≤0.82 |
≤0.39 |
≤0.82 |
≤0.38 |
≤0.82 |
≤0.38 |
|
Guanidinoacetate/ |
≤0.106 |
≤0.166 |
≤0.106 |
≤0.164 |
≤0.105 |
≤0.163 |
|
Guanidinoacetate/ |
≤0.038 |
≤0.036 |
≤0.038 |
≤0.036 |
≤0.039 |
≤0.036 |
|
|
51 Years |
52 Years |
53 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
17.0-52.2 |
11.9-34.3 |
17.1-52.3 |
12.0-34.3 |
17.3-52.4 |
12.2-34.3 |
|
Creatinine |
36.8-83.9 |
49.8-104.6 |
36.8-84.0 |
49.8-104.8 |
36.9-84.2 |
49.8-104.9 |
|
Guanidinoacetate |
1.2-3.1 |
1.7-3.3 |
1.2-3.1 |
1.7-3.2 |
1.2-3.1 |
1.6-3.2 |
|
Creatine/ |
≤0.82 |
≤0.37 |
≤0.82 |
≤0.37 |
≤0.82 |
≤0.38 |
|
Guanidinoacetate/ |
≤0.105 |
≤0.161 |
≤0.104 |
≤0.159 |
≤0.103 |
≤0.157 |
|
Guanidinoacetate/ |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
|
|
54 Years |
55 Years |
56 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
17.6-52.5 |
12.4-34.3 |
18.1-52.6 |
12.5-34.4 |
18.6-52.7 |
12.6-34.4 |
|
Creatinine |
37.0-84.4 |
49.8-105.0 |
37.1-84.5 |
49.8-105.2 |
37.2-84.7 |
49.8-105.3 |
|
Guanidinoacetate |
1.2-3.1 |
1.6-3.2 |
1.2-3.1 |
1.6-3.2 |
1.2-3.1 |
1.6-3.2 |
|
Creatine/ |
≤0.82 |
≤0.38 |
≤0.83 |
≤0.39 |
≤0.84 |
≤0.40 |
|
Guanidinoacetate/ |
≤0.102 |
≤0.155 |
≤0.100 |
≤0.154 |
≤0.099 |
≤0.152 |
|
Guanidinoacetate/ |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
≤0.039 |
≤0.036 |
|
|
57 Years |
58 Years |
59 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
19.2-52.9 |
12.7-34.4 |
19.9-53.1 |
12.8-34.3 |
20.5-53.3 |
12.8-34.2 |
|
Creatinine |
37.3-84.9 |
49.8-105.4 |
37.4-85.1 |
49.8-105.5 |
37.6-85.2 |
49.8-105.6 |
|
Guanidinoacetate |
1.2-3.0 |
1.6-3.2 |
1.3-3.0 |
1.6-3.2 |
1.3-3.0 |
1.6-3.2 |
|
Creatine/ |
≤0.84 |
≤0.40 |
≤0.85 |
≤0.41 |
≤0.86 |
≤0.42 |
|
Guanidinoacetate/ |
≤0.098 |
≤0.151 |
≤0.096 |
≤0.151 |
≤0.095 |
≤0.150 |
|
Guanidinoacetate/ |
≤0.039 |
≤0.036 |
≤0.038 |
≤0.036 |
≤0.038 |
≤0.036 |
|
|
60 Years |
61 Years |
62 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
21.0-53.6 |
12.8-34.1 |
21.5-53.9 |
12.7-34.0 |
21.9-54.2 |
12.6-33.9 |
|
Creatinine |
37.8-85.4 |
49.9-105.7 |
38.0-85.5 |
49.9-105.9 |
38.3-85.7 |
49.9-106.0 |
|
Guanidinoacetate |
1.3-2.9 |
1.6-3.2 |
1.3-2.9 |
1.6-3.1 |
1.3-2.9 |
1.6-3.1 |
|
Creatine/ |
≤0.87 |
≤0.43 |
≤0.87 |
≤0.44 |
≤0.88 |
≤0.44 |
|
Guanidinoacetate/ |
≤0.094 |
≤0.150 |
≤0.093 |
≤0.150 |
≤0.093 |
≤0.150 |
|
Guanidinoacetate/ |
≤0.037 |
≤0.036 |
≤0.036 |
≤0.035 |
≤0.036 |
≤0.035 |
|
|
63 Years |
64 Years |
65 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
22.2-54.6 |
12.4-33.7 |
22.3-55.0 |
12.3-33.6 |
22.5-55.5 |
12.2-33.4 |
|
Creatinine |
38.7-85.8 |
50.0-106.1 |
39.1-85.9 |
50.0-106.3 |
39.6-86.1 |
50.1-106.4 |
|
Guanidinoacetate |
1.3-2.8 |
1.6-3.1 |
1.3-2.8 |
1.6-3.1 |
1.3-2.8 |
1.6-3.1 |
|
Creatine/ |
≤0.88 |
≤0.45 |
≤0.89 |
≤0.46 |
≤0.89 |
≤0.46 |
|
Guanidinoacetate/ |
≤0.092 |
≤0.150 |
≤0.092 |
≤0.149 |
≤0.091 |
≤0.149 |
|
Guanidinoacetate/ |
≤0.035 |
≤0.035 |
≤0.034 |
≤0.034 |
≤0.034 |
≤0.034 |
|
|
66 Years |
67 Years |
68 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
22.6-55.9 |
12.3-33.1 |
22.7-56.3 |
12.3-32.8 |
22.9-56.7 |
12.5-32.4 |
|
Creatinine |
40.2-86.2 |
50.2-106.6 |
40.7-86.3 |
50.3-106.7 |
41.3-86.5 |
50.4-106.9 |
|
Guanidinoacetate |
1.3-2.7 |
1.6-3.1 |
1.3-2.7 |
1.6-3.0 |
1.4-2.7 |
1.6-3.0 |
|
Creatine/ |
≤0.90 |
≤0.47 |
≤0.90 |
≤0.48 |
≤0.90 |
≤0.48 |
|
Guanidinoacetate/ |
≤0.091 |
≤0.149 |
≤0.090 |
≤0.148 |
≤0.090 |
≤0.148 |
|
Guanidinoacetate/ |
≤0.034 |
≤0.034 |
≤0.033 |
≤0.034 |
≤0.033 |
≤0.034 |
|
|
69 Years |
70 Years |
≥ 71 Years |
|||
|
Female |
Male |
Female |
Male |
Female |
Male |
|
|
Creatine |
23.2-57.0 |
12.8-32.0 |
23.6-57.2 |
13.1-31.4 |
24.1-57.3 |
13.6-30.8 |
|
Creatinine |
41.9-86.6 |
50.5-107.1 |
42.4-86.8 |
50.7-107.4 |
42.8-86.9 |
50.8-107.6 |
|
Guanidinoacetate |
1.4-2.6 |
1.6-3.0 |
1.4-2.6 |
1.6-3.0 |
1.4-2.5 |
1.5-3.0 |
|
Creatine/ |
≤0.90 |
≤0.48 |
≤0.90 |
≤0.48 |
≤0.90 |
≤0.48 |
|
Guanidinoacetate/ |
≤0.090 |
≤0.148 |
≤0.090 |
≤0.148 |
≤0.090 |
≤0.148 |
|
Guanidinoacetate/ |
≤0.033 |
≤0.034 |
≤0.033 |
≤0.034 |
≤0.033 |
≤0.034 |
Method Description
A plasma sample is combined with stable isotope-labeled internal standards and acetonitrile. After centrifugation, an aliquot of this diluted sample is analyzed by injection onto liquid chromatography columns that separate the analytes from the bulk of the stable isotope dilution in the positive electrospray selected reaction monitoring mode using the Applied Biosystems API 3200 liquid chromatography tandem mass spectrometry system with Analyst software.(Bodamer OA, Bloesch SM, Gregg AR, Stockler-Ipsiroglu S, O'Brien WEO. Analysis of guanidinoacetate and creatine by isotope dilution electroscopy tandem mass spectrometry. Clin Chim Acta. 2001;308:173-178; Cognat S, Cheillan D, Piraud M, Roos B, Jakobs C, Vianey-Saban C. Determination of guanidinoacetate and creatine in urine and plasma by liquid chromatography-tandem mass spectrometry. Clin Chem. 2004;50(8):1459-1461; Sharer JD, Bodamer O, Longo N, Tortorelli S, Wamelink M, Young S. Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics. Genet Med. 2017;19[2]:256-263)
Day(s) Performed
Tuesday
Performing Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
82540
82565
82542
Forms
1. Biochemical Genetics Patient Information (T602)
2. If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.